Federal obstruction of justice under 18 U.S.C. § 1519 involves the destruction, alteration, or falsification of records in federal investigations and in bankruptcy proceedings.
Essentially, this statute criminalizes knowingly concealing or destroying documents with the intent to impede, obstruct, or influence an investigation by a federal agency or department.
For pharmaceutical executives, this often manifests when internal communications or clinical data are deleted during an active or even contemplated inquiry by the Food and Drug Administration (FDA) or the Department of Justice (DOJ).
The pharmaceutical industry operates under a microscope of regulatory oversight.
When a "quiet" or informal inquiry begins, such as a request for information about a drug's side effects or marketing practices, the legal obligation to preserve evidence is triggered immediately.
Under Section 1519, even the standard operation of a corporate "auto-delete" policy for emails can constitute criminal obstruction if the policy was not affirmatively suspended once the executive became aware of a potential federal investigation.
Eisner Gorin LLP is ready to assist. Book your consultation by calling (818) 781-1570 or filling out the contact form.
What is 18 U.S.C. § 1519?
Section 1519 was enacted as part of the Sarbanes-Oxley Act to close loopholes in federal obstruction laws.
Unlike other obstruction statutes, Section 1519 does not require the government to prove that a specific judicial proceeding was pending at the time of the document destruction. It is enough for the prosecution to show that the defendant acted in "contemplation" of such a proceeding.
For a pharmaceutical executive, "contemplation" can be triggered by a whistleblower complaint, an adverse event report that garners regulatory interest, or an informal letter of inquiry from the FDA.
If an executive allows an automated system to purge relevant emails after this point, they may face felony charges.
How Do Federal Prosecutors Prove Obstruction?
To secure a conviction under 18 U.S.C. § 1519, the government must prove three primary elements beyond a reasonable doubt:
- The Act: The defendant altered, destroyed, mutilated, concealed, covered up, falsified, or made a false entry in any record, document, or tangible object.
- The Intent: The defendant acted "knowingly." This means the action was not a mistake or an accident, though the executive need not necessarily know they were violating this specific statute.
- The Objective: The defendant acted with the intent to impede, obstruct, or influence the investigation or proper administration of any matter within the jurisdiction of any department or agency of the United States.
In the context of corporate audit records, the prosecution often focuses on the timing of the destruction.
If a "litigation hold" was not issued to the IT department immediately following a regulatory notification, the government will argue that the failure to stop "auto-delete" functions was a deliberate choice intended to hide incriminating evidence.
Is it Illegal to Delete Anything During Informal FDA Inquiries?
Many pharmaceutical executives mistakenly believe that formal subpoenas are the only trigger for document preservation. However, the FDA often conducts "informal" inquiries that do not initially involve a grand jury or a court order.
If an executive receives a phone call or email from a regulatory official requesting, for example, clarification on clinical trial data, the matter is officially "within the jurisdiction" of a federal agency.
Continuing to allow any communications to be deleted after this contact is a high-stakes gamble.
Federal investigators frequently use forensic software to recover deleted data, and the discovery of purged records often leads to a separate obstruction charge that is easier for a jury to understand than the underlying regulatory violation.
What are the Penalties for Federal Obstruction of Justice?
A conviction under 18 U.S.C. § 1519 is a Class C felony. The consequences for a pharmaceutical professional are often life-altering:
- Prison Time: A maximum sentence of up to 20 years in federal prison.
- Substantial Fines: Corporations can be fined millions, while individuals face fines up to $250,000 per count.
- Supervised Release: A period of mandatory supervision following imprisonment.
- Career Damage: Executives convicted of obstruction are often barred from working in any capacity for a company that receives federal funding or deals with Medicare/Medicaid.
Frequently Asked Questions
Do I need a subpoena to be charged with obstruction?
No. Liability can arise even before a formal proceeding begins.
Can deleting emails automatically be a crime?
Yes, if you knew an investigation was likely and failed to stop the deletion.
What if I didn't personally delete anything?
You may still be liable if you had authority and failed to act.
Is intent required?
Yes. Prosecutors must show you acted knowingly and with intent to obstruct.
Can companies be charged?
Yes. Both individuals and corporations can face liability.
Should I contact a lawyer early?
Yes. Early legal guidance is critical in federal investigations.
Hypothetical Case Study: The "Auto-Delete" Trap
Mr. A is the Chief Operations Officer of a mid-sized pharmaceutical company. The company receives a "soft" inquiry from the FDA regarding the off-label marketing of a new cardiovascular drug.
The letter asks for "voluntary cooperation" in providing marketing materials. Mr. A reads the letter but does not notify the IT department.
Two weeks later, the company's standard 30-day "auto-delete" policy purges the email accounts of three regional sales managers. These emails contained discussions about marketing the drug for unapproved uses.
The DOJ discovers the missing emails through a separate subpoena of the sales managers' personal devices.
They charge Mr. A with obstruction of justice under 18 U.S.C. § 1519, arguing that by failing to suspend the auto-delete policy after receiving the FDA letter, he knowingly allowed the destruction of records to impede the investigation.
The federal criminal defense team Eisner Gorin LLP focuses on the lack of "corrupt intent."
By examining the company's historical compliance records, the defense demonstrates that Mr. A had no direct role in the IT department's automated schedules and that the failure to issue a litigation hold resulted from a breakdown in administrative communication, not criminal intent to obstruct.
The defense also argues that the FDA's inquiry was so broad and informal that a reasonable person in Mr. A's position would not have "contemplated" a specific investigation into the deleted emails.
This strategy aims to shift the narrative from "intentional concealment" to "administrative oversight," seeking a dismissal or a significant reduction in charges.
Can Silence or Inaction Constitute Obstruction?
Under Section 1519, inaction, such as failing to stop an automated process, can be interpreted as an "act" of concealment.
This is particularly true for C-suite executives who have the authority to control corporate data. Obstruction under the Sarbanes-Oxley framework can be triggered by the "omission" of a preservation order.
Federal courts have broadly interpreted what constitutes a "matter within the jurisdiction" of a federal agency. This includes:
- Pre-compliance audits by the FDA.
- Inquiries by the Securities and Exchange Commission (SEC) into forgery of corporate records.
- Inquiries regarding the counterfeiting of proprietary medications.
Protecting Corporate Reputation and Freedom
For high-profile executives, the primary goal of a defense team is to keep the case out of the public eye. A public indictment for obstruction can lead to a plummeting stock price, loss of investor confidence, and permanent reputational damage.
By engaging in aggressive pretrial motion practice, defense counsel can often challenge the government's evidence before a trial ever begins.
In many instances, the government's case relies on the testimony of a "cooperating witness" or a whistleblower. Investigating the motives of these individuals is a cornerstone of a robust federal defense.
If the prosecution's narrative is built on the word of a disgruntled former employee, the credibility of the entire obstruction charge may be compromised.
Why isn't Technical Compliance a Defense?
"I was just following company policy" is rarely an effective defense in federal court. Section 1519 was designed specifically to override the "routine document retention" excuse.
If the government can prove that the executive knew the documents were relevant to a "contemplated" matter, the fact that the destruction happened automatically is irrelevant.
To mitigate risk, pharmaceutical companies must have:
- A clear protocol for immediate litigation holds.
- Direct lines of communication between legal counsel and the Chief Information Officer.
- Regular training for executives on the reach of 18 U.S.C. § 1519.
Contact a Federal Criminal Defense Attorney
Facing a federal investigation is an extremely vulnerable period for any pharmaceutical executive.
The line between a routine administrative task and a federal felony is dangerously thin under 18 U.S.C. § 1519. If you are aware of an ongoing FDA inquiry or have concerns about the preservation of electronic records, immediate legal intervention is required.
The federal criminal defense attorneys at Eisner Gorin LLP are well-versed in corporate governance and the aggressive tactics federal prosecutors use in obstruction-of-justice cases.
We work to protect your career, your company, and ensure that the government does not mischaracterize your actions. Schedule your consultation today. Our law firm is based in Los Angeles.
If you have one phone call from jail, call us! If you are facing criminal charges,